You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Company Profile

Taisho Pharmaceutical Co Ltd in Consumer Health

Sep 2011

Price: US$525

About this Report

About this Report


Euromonitor International's report on Taisho Pharmaceutical Co Ltd delivers a detailed strategic analysis of the company's business, examining its performance in the Consumer Health market and the global economy.

Company and market share data provide a detailed look at the financial position of Taisho Pharmaceutical Co Ltd, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Taisho Pharmaceutical Co Ltd This report examines:

  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of Taisho Pharmaceutical Co Ltd provides strategic intelligence on:

  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust

Euromonitor International's company profile reports are written by our Consumer Health research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery:
Reports are delivered in pdf format and can be downloaded from your online account (called My Pages) immediately after purchase.

Table of Contents

Table of Contents

Introduction

Scope

Strategic Evaluation

Taisho: Japanese Focus

Financial analysis: Fiscal 2010

Taisho 2011 forecasts

SWOT: Taisho Pharmaceutical Co Ltd

Strategic objectives and challenges

Competitive Positioning

Reliance on Japan holds back Taisho

Japanese fortunes influence Taisho’s performance

Johnson & Johnson leads pack despite recalls

Market Assessment

Taisho: strong presence in tonics and bottled nutritive drinks

Asia Pacific still offers strongest opportunities for Taisho

Geographic and Category Opportunities

Leverage Hoe acquisition to bring Taisho brands to Malaysia

Indonesia: Cross-border opportunities in consumer health

Lipovitan vulnerable to declines in Japanese market

Develop Lipovitan beauty tonic and bottled nutritive drink

Pan-Asia Pacific expansion should be Taisho’s priority

Consider expansion into medicated confectionery and generics

Consider expansion in analgesics through acquisition

Poor outlook in Japan analgesics

Hoe: A new armoury of tools for Taisho in medicated skin care

Taisho well positioned in hair loss treatments

Opportunities in medicated skin care

Brand Strategy

International expansion for Lipovitan crucial

Pabron: Potential for growth

Operations

Distribution strategy and manufacturing facilities

Recommendations

International expansion should remain the priority

Samples

Please update/install flash.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!